InvestorsHub Logo
icon url

Bluerinse

09/13/16 7:31 AM

#272401 RE: Protector #272400

Thank you CP... appreciate your sensible fact based approach ....as frustrated as I am I remain committed to the end
Lets hope this fall proves to be the turning point for this story....someone could definitely write a book on this story
IMO
icon url

stoneroad

09/13/16 7:34 AM

#272402 RE: Protector #272400

Very much looking forward to Wolchok's melanoma story!!
icon url

itsabouttime

09/13/16 9:01 AM

#272405 RE: Protector #272400

If so Partnerships should be forth coming.


"possibly holding the most valuable IP and pipelines in Immuno-Oncology (and other Immuno disciplines) around".
icon url

vinmantoo

09/13/16 12:15 PM

#272438 RE: Protector #272400

I think that, within the strategy of positioning Bavituximab as the component that BPs can use to make SOC against a competitor in mono Immuno-Oncology, there are going to be upfront payments PLUS product delivery for PI. Possibly that is why they review ALSO the AstraZeneca deal, placing ALL BP's on a same floor: "Pay up-front and deliver your product for PI and you can do PII/PIII yourself." The Sunrise stop opened this possibility as a side effect.



Yes, thank God Sunrise failed, otherwise PPHM would have lost that opportunity.
icon url

ku

09/13/16 9:36 PM

#272473 RE: Protector #272400

CP, just a response to your last line, the facts are that we are a manufacturing company for the next couple of years. Our shares will go thru a major Reverse Split (1-7 was taken out of proxy) and seems like the common stock on the shelf and PPHMP will not go thru the RS. What do you think about that? Now some of you guys are all happy that we will become profitable in 21 months. Blows my mind